REMS' Value Is Questioned

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93
Trade Publication
The article presents a report from the Tufts Center for the Study of Drug Development (CSDD) which reveals that those involve in the delivery of health care in the U.S. say on the uncertainty of the benefits of the Risk Evaluation & Mitigation Strategy (REMS) by Food and Drug Administration.


Related Articles

  • Innovation in Drug Development. Vogenberg, F. Randy // American Health & Drug Benefits;Feb/Mar2009, Vol. 2 Issue 2, p69 

    In this article the author discusses the challenges faced by the U.S. Food and Drug Administration (FDA) on innovation in drug development. The author, along with Cleveland Clinic's Steven Nissen, pointed out to the failings and problems of the FDA. He comments that the presidential election and...

  • 'National highway' offered for personalized medicine. McCARTY, MARK // Medical Device Daily;6/22/2010, Vol. 14 Issue 119, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have committed to further advance personalized medicine (PM), which is new in clinical practice in the U.S., through their Critical Path Initiative. The NIH will establish centers...

  • Hurdles Ahead for 'Cures' Legislation, PDUFA Renewal. WECHSLER, JILL // Pharmaceutical Executive;Aug2015, Vol. 35 Issue 8, p10 

    The article focuses on the hurdles against the 21st Century Cures Act from the U.S. Senate despite its approval from the House of Representatives. Topics discussed include the Food and Drug Administration's launch of the Prescription Drug User Fee Act (PDUFA), the user reauthorization process,...

  • Science, Surrogates & Stability. Wechsler, Jill // Pharmaceutical Executive;Jun99, Vol. 19 Issue 6, p18 

    Discusses the need to strengthen the science base of the United States Food and Drug Administration (FDA). Role of scientific expertise in a number of important regulatory initiatives; Why it is critical for the FDA to determine what data are needed to document the health benefit of a...

  • FDA's ability to affect treatment patterns appears limited.  // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p4 

    The article discusses research by S. H. Busch et al published in the January 1, 2010 issue of the journal "Psychiatric Services" which discussed the ability of the U.S. Food and Drug Administration (FDA) to influence the care received by patients.

  • Washington update. Wechsler, Jill // Formulary;Jan1997, Vol. 32 Issue 1, p100 

    Focuses on health care issues facing the US Food & Drug Administration (FDA) for the year 1997. Appointment of new FDA commissioner; Continuation of the FDA user-fee program; Restoration of solvency to Medicare; Enactment of policies related to growth of managed care.

  • REMS Seen as Opportunity.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article focuses on the significance of the Risk Evaluation and mitigation Strategies (REMS) of the U.S. Food and Drug Administration (FDA).

  • FDA Seeks Comments on ICH's GCP Guideline Update.  // CenterWatch Monthly;Jan2016, Vol. 23 Issue 1, p4 

    The article presents the comments sought by the government agency the U.S. Food and Drug Administration (FDA) on the draft guidance entitled "Guideline for Good Clinical Practice."

  • Herbal medicine at a crossroads Taylor, David // Environmental Health Perspectives;Sep1996, Vol. 104 Issue 9, p924 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics